Cargando…

Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report

Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ming-Jun, Chen, Yu-Chun, Cui, Xiao-Li, Yang, Qian, Xue, Qing-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/
https://www.ncbi.nlm.nih.gov/pubmed/37171300
http://dx.doi.org/10.1097/MD.0000000000033788
_version_ 1785040016886464512
author Wu, Ming-Jun
Chen, Yu-Chun
Cui, Xiao-Li
Yang, Qian
Xue, Qing-Liang
author_facet Wu, Ming-Jun
Chen, Yu-Chun
Cui, Xiao-Li
Yang, Qian
Xue, Qing-Liang
author_sort Wu, Ming-Jun
collection PubMed
description Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC. PATIENT CONCERNS: A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021. DIAGNOSIS: BCC and squamous lung cancer. INTERVENTIONS: Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy. OUTCOMES: Both BCC and squamous lung cancer were significantly reduced in size. CONCLUSION: After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed.
format Online
Article
Text
id pubmed-10174383
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101743832023-05-12 Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report Wu, Ming-Jun Chen, Yu-Chun Cui, Xiao-Li Yang, Qian Xue, Qing-Liang Medicine (Baltimore) 4200 Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC. PATIENT CONCERNS: A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021. DIAGNOSIS: BCC and squamous lung cancer. INTERVENTIONS: Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy. OUTCOMES: Both BCC and squamous lung cancer were significantly reduced in size. CONCLUSION: After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed. Lippincott Williams & Wilkins 2023-05-12 /pmc/articles/PMC10174383/ /pubmed/37171300 http://dx.doi.org/10.1097/MD.0000000000033788 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4200
Wu, Ming-Jun
Chen, Yu-Chun
Cui, Xiao-Li
Yang, Qian
Xue, Qing-Liang
Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title_full Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title_fullStr Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title_full_unstemmed Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title_short Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
title_sort tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: a case report
topic 4200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/
https://www.ncbi.nlm.nih.gov/pubmed/37171300
http://dx.doi.org/10.1097/MD.0000000000033788
work_keys_str_mv AT wumingjun tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport
AT chenyuchun tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport
AT cuixiaoli tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport
AT yangqian tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport
AT xueqingliang tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport